Dover has entered right into a definitive settlement to amass Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and control instruments for the biopharmaceutical, semiconductor and industrial sectors.
Malema’s merchandise will broaden Dover’s biopharma single-use manufacturing offering, which already contains Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with services in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in revenue during the full yr 2022.
When the deal closes, Malema will turn out to be a half of the PSG enterprise unit inside Dover’s Pumps & Process Solutions segment.
“We see an amazing long-term growth opportunity in the bioprocessing business pushed by a robust and growing pipeline of efficient novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of more efficient single-use production processes helps a strong outlook for our choices of single-use elements to end-customers. We imagine that pairing Malema’s technology with our current portfolio of single-use pumps for biopharma processing will tremendously enhance the accuracy and worth proposition of our solutions to our clients.”
เกจวัดแรงดันแก๊สco2 are methodically building out our biopharma platform via proactive capability additions, new product growth, and opportunistic acquisitions of highly-attractive niche part technologies,” said Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing technology and additional strengthens our sensor portfolio with new proprietary technology. In addition to attractive biopharma applications, we expect sturdy progress in the semiconductor space on the capability growth and re-shoring tailwinds.”
Share